Aerovate Therapeutics, Inc. (AVTE)
$
2.68
Key metrics
Financial statements
Free cash flow per share
Market cap
Price to sales ratio
Debt to equity
Current ratio
Income quality
Average inventory
ROE
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company incorporated in 2018 and headquartered in Waltham, Massachusetts, is dedicated to developing innovative drugs that aim to improve the quality of life for patients suffering from rare cardiopulmonary diseases in the United States. The company's focus is on advancing AV-101, a dry powder inhaled formulation of imatinib designed for the treatment of pulmonary arterial hypertension, which is currently undergoing a Phase 2b/Phase 3 trial. The operating income ratio is 0.00 indicating the company's operational profitability margin. The gross profit stands at $0.00 highlighting the company's profitability from core operations. Additionally, the EBITDA is -$74,314,000.00 a key indicator of the company's operational profitability. The earnings per share (EPS) is reported at -$2.44 reflecting the company's profitability on a per-share basis. Furthermore, the net total of other income and expenses is $5,023,000.00 which reflects non-core financial activities relevant to their business operations. In terms of market presence, the stock is affordable at $93.80 making it suitable for budget-conscious investors. The stock has an average trading volume of 7,993.00 indicating moderate liquidity that may appeal to a diverse range of investors. With a market capitalization of $77,679,800.00 the company is classified as a small-cap player, providing potential growth opportunities within its sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving advancements in therapeutics. Additionally, it belongs to the Healthcare sector, which is known for fostering innovation and growth, thereby enhancing the company's standing within the biopharmaceutical domain.
What is Aerovate Therapeutics, Inc. (AVTE)'s stock forecast?
Analysts predict Aerovate Therapeutics, Inc. stock to fluctuate between $2.63 (low) and $884.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aerovate Therapeutics, Inc.'s market capitalization?
As of 2025-04-28, Aerovate Therapeutics, Inc.'s market cap is $77,679,800, based on 28,985,000 outstanding shares.
How does Aerovate Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aerovate Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Aerovate Therapeutics, Inc. pay dividends?
Aerovate Therapeutics, Inc. pays dividends. The current dividend yield is 0%, with a payout of $2.40 per share.
How can I buy Aerovate Therapeutics, Inc. (AVTE) stock?
To buy Aerovate Therapeutics, Inc. (AVTE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AVTE. Place an order (Market, Limit, etc.).
What is the best time to invest in Aerovate Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Aerovate Therapeutics, Inc. stock ever split?
Aerovate Therapeutics, Inc.'s last stock split was 1:35 on 2025-04-29.
How did Aerovate Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.44 | Growth: -14.98%.
Where can I find Aerovate Therapeutics, Inc.'s investor relations reports?
Visit https://aerovatetx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aerovate Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aerovate Therapeutics, Inc. stock?
All-time high: $96.95 (2025-04-28) | All-time low: $1.25 (2024-06-20).
What are the key trends affecting Aerovate Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. (“Aerovate”). The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol “JBIO.
prnewswire.com
a month ago
—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass. , April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger.
prnewswire.com
2 months ago
Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass. , April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement").
prnewswire.com
2 months ago
Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass. , April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate.
businesswire.com
2 months ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences. Pursuant to the terms of the agreement, shareholders of Aerovate will own approximately 1.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the m.
businesswire.com
5 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
globenewswire.com
7 months ago
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.
prnewswire.com
7 months ago
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences.
prnewswire.com
7 months ago
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics, Inc. (NASDAQ: AVTE)'s merger with Jade Biosciences. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company.
businesswire.com
7 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
See all news
